van Rooy, Inge; Cakir-Tascioglu, Serpil; Couraud, Pierre-Olivier; Romero, Ignacio A.; Weksler, Babette; Storm, Gert; Hennink, Wim E.; Schiffelers, Raymond M. and Mastrobattista, Enrico
Due to copyright restrictions, this file is not available for public download
Click here to request a copy from the OU Author.
|DOI (Digital Object Identifier) Link:||http://dx.doi.org/doi:10.1007/s11095-010-0053-6|
|Google Scholar:||Look up in Google Scholar|
Transport of drugs to the brain is limited by the blood-brain barrier. New, specific brain endothelium ligands can facilitate brain-specific delivery of drugs.
We used phage display in an in situ brain perfusion model to screen for new brain endothelium peptide ligands.
Two phage clones, displaying 15 amino acid-peptides (GLA and GYR) that were selected for brain binding in the mouse model, showed significant binding to human brain endothelium (hCMEC/D3), compared to a random control phage. This binding was not seen for other human endothelial cells (HUVEC). Binding to hCMEC/D3 cells was dose dependent. When phage GLA and GYR were individually perfused through the murine brain, their ability to bind to the brain was 6-fold (GLA) and 5-fold (GYR) higher than the control phage. When compared to lung perfusion, phage showed an 8.5-fold (GYR) and 48-fold (GLA) preference for brain over lung compared to the control.
These results indicate that two new peptide ligands have been identified that may be used for specific targeting of drugs to the blood-brain barrier.
|Item Type:||Journal Article|
|Copyright Holders:||2010 The Authors|
|Extra Information:||This article is published with open access at www.springerlink.com|
|Keywords:||blood-brain barrier; brain targeting; peptide ligand; phage display; targeting ligand|
|Academic Unit/Department:||Science > Life, Health and Chemical Sciences|
|Depositing User:||Astrid Peterkin|
|Date Deposited:||06 Jan 2011 12:18|
|Last Modified:||27 Nov 2012 15:52|
Actions (login may be required)
|Public: Report issue / request change|